<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891694</url>
  </required_header>
  <id_info>
    <org_study_id>EGN_2016_8</org_study_id>
    <nct_id>NCT02891694</nct_id>
  </id_info>
  <brief_title>Metalloproteinases and Recurrent Corneal Erosion Syndrome</brief_title>
  <acronym>MERCURE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy
      of the basement membrane or following corneal trauma. This syndrome is characterized by
      recurrent episodes of ocular pain more or less associated with localized separations between
      the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage
      abnormalities between these two corneal layers. This could be the result of an increased
      expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the
      basement membrane.

      The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of
      matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of
      such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3
      in the RCE syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cells</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Corneal Erosion Syndrome</condition>
  <arm_group>
    <arm_group_label>recurrent corneal erosion</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>control patients (refractive surgery)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>in vitro immuno-histo-chemical analysis of corneal epithelium</intervention_name>
    <arm_group_label>recurrent corneal erosion</arm_group_label>
    <arm_group_label>control patients (refractive surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Recurrent Corneal Erosion Syndrome and control patients (undergoing
        photorefractive surgical keratectomy)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and
             therapeutic photokeratectomy scheduled

          -  Photorefractive surgical keratectomy (control patients)

        Exclusion Criteria:

          -  Opposition to participation in the study

          -  Known pregnancy or breast-feeding patient

          -  No medical insurance coverage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric GABISON, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation OPH A de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence SALOMON, MD, PhD</last_name>
    <phone>0033148036431</phone>
    <email>lsalomon@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation Opthalmologique A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric GABISON</last_name>
      <email>egabison@for.paris</email>
    </contact>
    <contact_backup>
      <last_name>Damien GUINDOLET</last_name>
      <email>dguindolet@for.paris</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

